{"id":4490,"date":"2026-11-21T09:00:00","date_gmt":"2026-11-21T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4490"},"modified":"2026-11-21T09:33:34","modified_gmt":"2026-11-21T13:33:34","slug":"saturday-rounds-week-of-november-14-20-2026","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4490","title":{"rendered":"Saturday Rounds: Week of November 14\u201320, 2026"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261121_Insilens_Saturday_Rounds-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4491\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261121_Insilens_Saturday_Rounds-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261121_Insilens_Saturday_Rounds-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261121_Insilens_Saturday_Rounds-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261121_Insilens_Saturday_Rounds-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261121_Insilens_Saturday_Rounds.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Hard endpoints win, gaps get rejected, markets fall.<\/strong><\/p>\n<p>Weekly Biotech Signal Review \u00b7 Completed reporting week: November 14\u2013November 20, 2026 \u00b7 Published November 21, 2026<\/p>\n<p><strong>Report at a glance:<\/strong> SELLAS reported a Phase 3 survival benefit in AML and the FDA approved four novel drugs, but rejected Summit\u2019s ivonescimab for lack of a survival benefit while Pfizer, J&amp;J and Isomorphic committed billions in a week when the S&amp;P 500 fell 8.6%.<\/p>\n<h3>The Lede<\/h3>\n<p>SELLAS announced on November 17 that the Phase 3 REGAL trial of galinpepimut-S, a WT1-directed vaccine, met its primary overall-survival endpoint in AML patients in second or later remission who cannot undergo allogeneic transplant: median survival 24.0 versus 14.7 months, hazard ratio 0.59 (41% risk reduction), two-sided p=0.035, after the prespecified 80 deaths. About 126 patients were randomized 1:1, open label, against investigator-selected best available treatment. The same week the FDA issued a complete response letter for Summit\u2019s ivonescimab because overall survival was not statistically significant. Full confidence intervals, curves and subsequent-therapy data for REGAL have not been released, and FDA discussions are planned for 2027.<\/p>\n<table>\n<thead>\n<tr>\n<th>Signal Importance<\/th>\n<th>Signal Direction<\/th>\n<th>Confidence in Facts<\/th>\n<th>Confidence in Interpretation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>5 \/ 5<\/td>\n<td>Positive for REGAL; negative for evidence built on PFS and China-heavy data<\/td>\n<td>High<\/td>\n<td>Moderate<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Weekly validation gate: importance is 5\/5 because a randomized survival win and a survival-based FDA rejection arrived within days. Interpretation is moderate because REGAL is a topline, open-label result with p=0.035, a heterogeneous control arm and enrollment that differs slightly between sources (126 in the release, 127 in the registry).<\/em><\/p>\n<h3>Signal of the Week: REGAL Shows Survival in a Narrow AML Population<\/h3>\n<p>REGAL is the highest-strength clinical signal because it was randomized and used death as the endpoint in a population with limited maintenance options. If the full analysis holds, galinpepimut-S could offer a tolerable, outpatient alternative to observation or low-intensity regimens for patients who cannot reach transplant. The company describes the vaccine as generally well tolerated.<\/p>\n<p>The strongest counterargument is statistical and clinical fragility: p=0.035 leaves little margin, the open-label control arm allowed observation, hypomethylating agents, venetoclax or low-dose cytarabine, and post-randomization therapy, censoring and subgroup balance are undisclosed. The readout supports regulatory engagement; it does not establish approval or validate WT1 targeting more broadly.<\/p>\n<h3>The Week in Five<\/h3>\n<p><strong>Regulatory<\/strong> \u2014 The FDA issued a complete response letter (announced November 15, after the November 14 goal date) for ivonescimab plus chemotherapy in previously treated EGFR-mutated NSCLC: substantial evidence of effectiveness was not established without a statistically significant overall-survival improvement, and Fierce Pharma reports the FDA asked for a new global trial and noted that 93% of PFS events occurred in China (the letter itself was not public when we checked). The FDA\u2019s novel-approvals list shows four approvals: adrabetadex (November 17; first therapy shown to reduce risk of death in infantile-onset Niemann-Pick type C), neladalkib (November 17; ALK-positive NSCLC), venglustat (November 18; neurological manifestations of Gaucher disease type 3, ahead of a November 25 goal date) and cemdisiran (November 18; anti-AChR-positive generalized myasthenia gravis).<\/p>\n<p><strong>Clinical<\/strong> \u2014 SELLAS REGAL (above). Merck announced on November 17 that it is ending the nemtabrutinib program after an independent data monitoring committee said benefits in BELLWAVE-011 may not outweigh risks, covering BELLWAVE-008 and -010 too. Celldex reported on November 19 that Phase 2 barzolvolimab missed its primary and key secondary endpoints in 131 patients with atopic dermatitis, ended development in that indication, and said its chronic urticaria program and a planned 2027 BLA are unaffected.<\/p>\n<p><strong>Deals<\/strong> \u2014 Pfizer licensed three pre-IND in vivo CAR-T autoimmune programs from Starna Therapeutics outside Greater China for $330 million upfront and up to $2.3 billion in milestones plus royalties (about $2.63 billion total); the platform pairs a targeted lipid nanoparticle with RNA, and Pfizer holds options on Greater China. J&amp;J agreed on November 16 to acquire Ollin Biosciences for $2.2 billion upfront plus about $1.125 billion in milestones, with Blackstone separately funding $750 million of Phase 3 development of OLN324, a bispecific antibody for wet AMD and diabetic macular edema; close is expected before year-end.<\/p>\n<p><strong>Platform<\/strong> \u2014 Two Nature Medicine papers (published this week according to the reference file) characterize enterocolitis after BCMA CAR-T, mainly cilta-cel: a multicenter study reports only 32% of affected patients had resolution at last follow-up with some deaths attributed to the condition, and a Mount Sinai-linked study reports persistent mucosal CAR-T cells and inflammatory remodeling, with two patients improving on a JAK1 inhibitor. The reference file\u2019s AAV.APR31 CD7-targeted paper and inducible-CAR papers were not individually verified.<\/p>\n<p><strong>China<\/strong> \u2014 Ivonescimab\u2019s rejection illustrates the translation risk for China-heavy datasets, and Starna\u2019s deal is another China-originated asset licensed ex-China. The reference file\u2019s HUTCHMED approvals, JW reimbursement item and Kelun board change could not be confirmed and are not reported.<\/p>\n<h3>The Analyst\u2019s Take<\/h3>\n<p>Observed pattern: regulators and sponsors rewarded or punished the evidence they could see. REGAL reached a survival endpoint; the FDA refused ivonescimab on survival and geographic representativeness; Merck stopped a BTK inhibitor on a monitoring-committee benefit-risk call; Celldex ended an indication on efficacy below its own hurdle. FDA approvals for adrabetadex (survival) and cemdisiran, venglustat and neladalkib also arrived in a week otherwise dominated by capital.<\/p>\n<p>Explicit inference: capital was allocated to delivery and discovery infrastructure ahead of clinical proof. Pfizer paid $330 million for preclinical in vivo CAR-T programs, and Isomorphic raised $5 billion without disclosing a human trial. Capital validated strategic demand for programmability and delivery, not patient benefit. The competing interpretation is clustering: these events may share no cause, and the market selloff may have set the week\u2019s tone more than any evidentiary standard. The thesis strengthens if future in vivo systems show selective human transfection and controllable expression; it weakens if capital-backed platforms advance without translational control.<\/p>\n<h3>Evidence Classification<\/h3>\n<table>\n<thead>\n<tr>\n<th>Verified facts<\/th>\n<th>Company claims<\/th>\n<th>Explicit inference<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>REGAL topline numbers, the ivonescimab CRL basis, the four FDA approvals, Merck\u2019s and Celldex\u2019s decisions, the Pfizer\u2013Starna and J&amp;J\u2013Ollin terms, Isomorphic\u2019s Series C, the S&amp;P 500 and SPY moves and the PDUFA dates were checked against company releases, the FDA, SEC filings and named trade press.<\/td>\n<td>SELLAS\u2019 \u201cclinically meaningful\u201d and tolerability claims, Ollin\u2019s head-to-head claim against Vabysmo, Starna\u2019s platform description and Celldex\u2019s \u201churdle rate\u201d rationale are sponsor statements.<\/td>\n<td>\u201cCapital validated demand, not benefit\u201d and the evidence-versus-capital split are interpretations.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Market &amp; Capital Pulse<\/h3>\n<p><strong>Observed market facts<\/strong><\/p>\n<p>Measurement window: Friday, November 13 close to Friday, November 20 close. The S&amp;P 500 fell about 8.6% for the week, closing Friday at 6,910.39 (down 3.7% on the day, the seventh straight loss), its worst week since April 2025 and more than 10% below its October 6 record; the Nasdaq fell about 10.0%. SPY closed at 689.81 on Yahoo\u2019s quote page against 754.37 the prior Friday, a 8.56% decline; Yahoo\u2019s history table shows 693.59 and one closing report shows 690.87, so the exact SPY figure varies by source. XBI closed at 144.12 on Thursday, November 19, down 4.3% from 150.55 for the week to that point; we could not confirm the Friday close (a Yahoo snapshot showed about 141 intraday, down roughly 2%), so no full-week XBI return is reported. The reference file\u2019s 140.18 (down 6.9%) is plausible but unconfirmed.<\/p>\n<p>Catalyst dispersion exceeded the index move. SELLAS shares rose about 157% on the REGAL day (sources range 156\u2013161%), opening at $24.00 against a $7.47 prior close, then fell after the company priced a $150 million public offering at $13.00 per share; whether it closed in-window was not confirmed. Summit fell about 16% to roughly $11.82 on the first session after the CRL, though sources report 12% to 22%.<\/p>\n<p><strong>Capital and strategic appetite<\/strong><\/p>\n<p>Private capital: Isomorphic Labs closed a $5 billion Series C co-led by Greenoaks and Sequoia, with a16z and Alphabet participating, months after a $2.1 billion round in May; the company has not named a human clinical asset. The reference file\u2019s five other private rounds were not individually verified and are not counted. No IPO or follow-on is verified as closed in-window (Prime Medicine\u2019s $143.7 million closed November 12). The reference file\u2019s nChroma restructuring and its workforce impact were not verified.<\/p>\n<p>Inference, not causation: in a sharply falling market, money still went to large strategic bets and platform infrastructure, while the follow-on reaction in SELLAS shows that financing risk can dominate after the first move.<\/p>\n<h3>Deal Appetite and Restructuring<\/h3>\n<p>Two verified transactions carried $2.53 billion of upfront cash ($2.2 billion J&amp;J\u2013Ollin, $330 million Pfizer\u2013Starna) and about $3.425 billion of contingent milestones ($1.125 billion and $2.3 billion), excluding royalties. Blackstone\u2019s $750 million Phase 3 development funding for Ollin\u2019s OLN324 is separate and not a purchase price. Both buyers used external or deferred-risk structures: Pfizer paid for pre-IND programs, and J&amp;J paired an acquisition with third-party trial financing. CNBC reports the Ollin deal at up to $3.3 billion; the sum of the upfront and milestone figures is $3.325 billion, which we treat as the same headline.<\/p>\n<p>The reference file lists four further deals (Sanofi\u2013Seawolf, Lilly\u2013Stipple, AbbVie\u2013DISCO, Innogen\u2013Arcera) and six leadership changes; none could be verified and none are reported.<\/p>\n<h3>By the Numbers<\/h3>\n<table>\n<thead>\n<tr>\n<th>Category<\/th>\n<th>Verified count or value<\/th>\n<th>Scope note<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>FDA approvals<\/td>\n<td>4<\/td>\n<td>Adrabetadex, neladalkib, venglustat, cemdisiran (FDA novel approvals list). The reference file\u2019s EC and NMPA approvals were not verified.<\/td>\n<\/tr>\n<tr>\n<td>Complete response letters<\/td>\n<td>1<\/td>\n<td>Ivonescimab (Summit); announced Nov 15.<\/td>\n<\/tr>\n<tr>\n<td>Readouts and program decisions<\/td>\n<td>4<\/td>\n<td>SELLAS REGAL (positive); Merck nemtabrutinib (stopped); Celldex barzolvolimab AD (stopped); ivonescimab CRL counted above.<\/td>\n<\/tr>\n<tr>\n<td>Acquisitions and licenses<\/td>\n<td>2<\/td>\n<td>J&amp;J\u2013Ollin ($2.2B upfront); Pfizer\u2013Starna ($330M upfront).<\/td>\n<\/tr>\n<tr>\n<td>Verified upfront \/ contingent<\/td>\n<td>$2.53B \/ about $3.425B<\/td>\n<td>Excludes royalties and Blackstone\u2019s separate $750M.<\/td>\n<\/tr>\n<tr>\n<td>Private rounds<\/td>\n<td>1 \/ $5B<\/td>\n<td>Isomorphic Labs Series C; other reference-file rounds not verified.<\/td>\n<\/tr>\n<tr>\n<td>IPO and follow-on closings<\/td>\n<td>0 verified<\/td>\n<td>SELLAS priced a $150M offering at $13.00; close not confirmed.<\/td>\n<\/tr>\n<tr>\n<td>Material restructurings, leadership changes<\/td>\n<td>Not verified<\/td>\n<td>Reference-file items (nChroma; six roles) not independently confirmed.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Watching Next Week<\/h3>\n<p><em>Resolution of last week\u2019s calendar: ivonescimab\u2019s November 14 goal date ended in a CRL. Windward\u2019s IPO close, the CTAD sessions (November 16\u201319) and Beam\u2019s year-end BLA timing were not re-verified for this edition.<\/em><\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Catalyst<\/th>\n<th>Evidence status<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Nov 22 (Sun)<\/td>\n<td>Capricor deramiocel (DMD) PDUFA goal date<\/td>\n<td>Confirmed; review was extended three months after additional HOPE-3 data and follows a July 2025 CRL. Action may come before the nominal date.<\/td>\n<\/tr>\n<tr>\n<td>Nov 22 (Sun)<\/td>\n<td>Savara molgramostim (autoimmune PAP) PDUFA goal date<\/td>\n<td>Confirmed in aggregator and company filings.<\/td>\n<\/tr>\n<tr>\n<td>Nov 27 (Fri)<\/td>\n<td>BridgeBio BBP-418 (LGMD2I\/R9) PDUFA goal date<\/td>\n<td>Confirmed in company filing.<\/td>\n<\/tr>\n<tr>\n<td>Nov 28 (Sat)<\/td>\n<td>PolyPid D-PLEX100 (colorectal surgical-site infection) PDUFA goal date<\/td>\n<td>Confirmed; Priority Review; a Saturday date, so action may come earlier.<\/td>\n<\/tr>\n<tr>\n<td>Nov 23<\/td>\n<td>NeOnc NEO212 FDA Type B meeting<\/td>\n<td>From the reference file; not independently confirmed.<\/td>\n<\/tr>\n<tr>\n<td>Before year-end<\/td>\n<td>J&amp;J\u2013Ollin close; Beam risto-cel BLA as early as year-end<\/td>\n<td>Company guidance.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>What Would Change Our View<\/h3>\n<p><strong>Upgrade<\/strong> \u2014 REGAL\u2019s full survival curves, hazard-ratio confidence interval, subgroup analyses and subsequent-therapy accounting remaining coherent, followed by FDA agreement on a filing path, would strengthen the case for hard-endpoint evidence in narrow populations.<\/p>\n<p><strong>Downgrade<\/strong> \u2014 First-human in vivo CAR-T programs showing broad off-target transfection, poor persistence, or cytokine and infection risk would erode the manufacturing advantage claimed over ex vivo products.<\/p>\n<p><strong>Falsify<\/strong> \u2014 If capital-backed delivery and AI platforms fail to produce reproducible human target engagement while controlled programs with hard endpoints also fail to sustain benefit, the thesis that evidence quality is the main differentiator would be falsified.<\/p>\n<h3>Evidence Base<\/h3>\n<p><em>Sources are listed in order of first citation. Discrepancies versus the reference file used for this edition: SPY\u2019s November 20 close is 689.81 (Yahoo quote page, matches the reference), 693.59 (Yahoo history table) or 690.87 (one closing report); XBI\u2019s Friday close of 140.18 could not be confirmed (Yahoo showed about 141 intraday; the November 19 close was 144.12); SELLAS\u2019 one-day gain is 156%, 157% or 161% depending on the source; Summit\u2019s first-session decline is 12% to 22% against the reference\u2019s 16.5%; REGAL enrollment is 126 in the release and 127 in the registry; the reference file reports no in-window follow-on, but SELLAS priced a $150 million offering. Left out as unverified: seven approvals (EC, NMPA, HUTCHMED), Belite\u2019s review extension, Sanofi\u2013Seawolf, Lilly\u2013Stipple, AbbVie\u2013DISCO and Innogen\u2013Arcera, the five other private rounds, the nChroma restructuring, six leadership changes, the CD7-AAV and inducible-CAR papers, and NeOnc\u2019s Type B meeting.<\/em><\/p>\n<ol>\n<li><a href=\"https:\/\/ir.sellaslifesciences.com\/news\/News-Details\/2026\/SELLAS-Life-Sciences-Announces-Positive-Pivotal-Phase-3-REGAL-Trial-Data-Showing-Immunotherapeutic-Cancer-Vaccine-Galinpepimut-S-GPS-Demonstrated-a-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Overall-Survival-in-Patients-with-A\/default.aspx\">SELLAS, Positive Pivotal Phase 3 REGAL Trial Data for Galinpepimut-S in AML (Nov 17, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.targetedonc.com\/view\/galinpepimut-s-regal-phase-3-overall-survival-aml\">Targeted Oncology, Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML<\/a><\/li>\n<li><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04229979\">ClinicalTrials.gov, REGAL (NCT04229979)<\/a><\/li>\n<li><a href=\"https:\/\/www.fiercepharma.com\/pharma\/fdas-complete-response-letter-summit-ivonescimab-cites-china-heavy-data-beyond-survival-miss\">Fierce Pharma, FDA\u2019s complete response letter for Summit\u2019s ivonescimab cites China-heavy data beyond survival miss<\/a><\/li>\n<li><a href=\"https:\/\/smmttx.com\/news\/press-releases\/news-details\/2026\/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application\/default.aspx\">Summit Therapeutics, Update Regarding Ivonescimab Biologics License Application<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2026\">FDA, Novel Drug Approvals for 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.neurologylive.com\/view\/fda-approves-adrabetadex-first-therapy-improve-survival-infantile-onset-niemann-pick-disease-type-c\">NeurologyLive, FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C<\/a><\/li>\n<li><a href=\"https:\/\/www.neurologylive.com\/view\/fda-approves-cemdisiran-as-new-treatment-generalized-myasthenia-gravis\">NeurologyLive, FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis<\/a><\/li>\n<li><a href=\"https:\/\/www.merck.com\/news\/merck-announces-update-on-bellwave-clinical-development-program-evaluating-nemtabrutinib\/\">Merck, Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib<\/a><\/li>\n<li><a href=\"https:\/\/ir.celldex.com\/news-releases\/news-release-details\/celldex-reports-results-phase-2-study-barzolvolimab-atopic\">Celldex, Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis<\/a><\/li>\n<li><a href=\"https:\/\/endpoints.news\/pfizer-gets-into-in-vivo-car-t-through-licensing-deal-with-starna-therapeutics\/\">Endpoints News, Pfizer gets into in vivo CAR-T through licensing deal with Starna Therapeutics<\/a><\/li>\n<li><a href=\"https:\/\/pharmacally.com\/pfizer-starna-in-vivo-car-t-licensing-autoimmune-diseases\/\">Pharmacally, Pfizer Pays $330M Upfront for Starna\u2019s In Vivo CAR-T Programs<\/a><\/li>\n<li><a href=\"https:\/\/www.investor.jnj.com\/investor-news\/news-details\/2026\/Johnson--Johnson-to-acquire-Ollin-Biosciences-and-late-stage-bispecific-antibody-with-best-in-class-potential-in-ophthalmology\/default.aspx\">Johnson &amp; Johnson, to acquire Ollin Biosciences<\/a><\/li>\n<li><a href=\"https:\/\/www.biospace.com\/deals\/j-j-pays-2-2b-upfront-for-ollin-taps-blackstone-to-fund-eye-disease-trial\">BioSpace, J&amp;J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial<\/a><\/li>\n<li><a href=\"https:\/\/www.isomorphiclabs.com\/articles\/isomorphic-labs-announces-series-c-investment-round\">Isomorphic Labs, announces Series C investment round<\/a><\/li>\n<li><a href=\"https:\/\/www.biospace.com\/drug-development\/isomorphic-labs-breaks-biotech-vc-fundraising-record-with-5b-series-c\">BioSpace, Isomorphic Labs breaks biotech VC fundraising record with $5B series C<\/a><\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41591-026-04783-y\">Nature Medicine, Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy<\/a><\/li>\n<li><a href=\"https:\/\/scholars.mssm.edu\/en\/publications\/persistence-of-mucosal-car-t-cells-and-inflammatory-remodeling-in\/\">Mount Sinai, Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy<\/a><\/li>\n<li><a href=\"https:\/\/www.cnbc.com\/2026\/11\/19\/stock-market-today-live-updates.html\">CNBC, Stock Market Today (Nov 19, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/stocktwits.com\/news-articles\/markets\/equity\/nasdaq-100-ends-worst-week-since-2020-s-and-p-500-in-correction-territory-as-ai-rout-sours-sentiment-ant-nvda-ttwo-zs-crwd-in-focus\/cNbm3xQR91W\">Stocktwits, Nasdaq 100 Ends Worst Week Since 2020, S&amp;P 500 In Correction Territory<\/a><\/li>\n<li><a href=\"https:\/\/finance.yahoo.com\/quote\/SPY\/history\/\">Yahoo Finance, SPY quote and history<\/a><\/li>\n<li><a href=\"https:\/\/finance.yahoo.com\/quote\/XBI\/\">Yahoo Finance, XBI quote<\/a><\/li>\n<li><a href=\"https:\/\/www.ssga.com\/us\/en\/intermediary\/etfs\/state-street-spdr-sp-biotech-etf-xbi\">SSGA, XBI fund page<\/a><\/li>\n<li><a href=\"https:\/\/www.investing.com\/news\/stock-market-news\/sellas-life-sciences-stock-falls-on-150m-stock-offering-5034146\">Investing.com, Sellas Life Sciences stock falls on $150M stock offering<\/a><\/li>\n<li><a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/summit-stock-falls-fda-rejection-161300178.html\">Yahoo Finance, Summit Stock Falls on FDA Rejection for Lung Cancer Drug<\/a><\/li>\n<li><a href=\"https:\/\/globalgenes.org\/raredaily\/fda-extends-pdufa-date-for-capricors-dmd-therapy\/\">Global Genes, FDA Extends PDUFA Date for Capricor\u2019s DMD Therapy<\/a><\/li>\n<li><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1160308\/000119312526344585\/svra-20260630.htm\">Savara, 10-Q (SEC), molgramostim target action date<\/a><\/li>\n<li><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1743881\/000174388126000034\/bbio-20260930.htm\">BridgeBio, 10-Q (SEC), BBP-418 target action date<\/a><\/li>\n<li><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001611842\/000121390026118486\/ea031183401ex99-1.htm\">PolyPid, Form 6-K (SEC), D-PLEX100 target action date<\/a><\/li>\n<\/ol>\n<p>Until next Saturday: follow the evidence, not the noise.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hard endpoints win, gaps get rejected, markets fall. Weekly Biotech Signal Review \u00b7 Completed reporting week: November 14\u2013November 20, 2026 \u00b7 Published November 21, 2026 Report at a glance: SELLAS reported a Phase 3&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4491,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[250,251,249],"class_list":["post-4490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weekly-market-insight","tag-biotech-markets","tag-ma","tag-weekly-digest"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4490"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4490\/revisions"}],"predecessor-version":[{"id":4492,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4490\/revisions\/4492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4491"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}